ストックスクリーナーアプリを入手
182.28
1.86%
3.32
プレマーケット:
182.00
-0.28
-0.15%
前日終値:
$178.96
開ける：
$181.36
24時間の取引高:
1.74M
Relative Volume:
0.91
時価総額：
$282.69B
収益：
$60.48B
当期純損益:
$10.40B
株価収益率:
54.74
EPS:
3.3297
ネットキャッシュフロー:
$8.05B
1週間 パフォーマンス:
+0.26%
1か月 パフォーマンス:
+0.23%
6か月 パフォーマンス:
+101.88%
1年 パフォーマンス:
+147.19%
1日の値動き範囲:
$180.39
$183.67
1週間の範囲:
$177.88
$186.12
52週間の値動き範囲:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
182.28 | 282.69B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,160.95 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.33 | 573.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.77 | 397.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.76 | 298.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.92 | 293.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca PLC (AZN) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know - Yahoo Finance Singapore
AstraZeneca PLC Stock (US6549022043): Obesity Drug Elecoglipron Heads Into Phase 3 As Shares Climb - AD HOC NEWS
ASTRAZENECA : Deutsche Bank maintains a Sell rating - marketscreener.com
ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations - Citeline News & Insights
Jim Cramer on AstraZeneca: “On Track to Hit the Ambitious Long-Term Financial Targets” - Yahoo Finance
Hansa Biopharma appoints Head of Business Development from AstraZeneca - marketscreener.com
AstraZeneca advances oral GLP-1 elecoglipron into phase 3 - MSN
AstraZeneca PLC stock (US6549022043): obesity drug data and pipeline momentum keep investors alert - AD HOC NEWS
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - Benzinga
Functional genomics and AI drive novel target discovery at AstraZeneca - Select Science
ASTRAZENECA : JP Morgan remains its Buy rating - marketscreener.com
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA - Clinical Trials Arena
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth - GlobeNewswire Inc.
AstraZeneca Advances Obesity, Diabetes Medication Elecoglipron to Phase 3 Trial - marketscreener.com
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
NYLIM VP Income Builder Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
BofA reiterates Buy on AstraZeneca stock, cites adjuvant trial outlook By Investing.com - Investing.com South Africa
AstraZeneca progresses elecoglipron after positive phase IIb results - London South East
Why is CAMBRIA-1 emerging as AstraZeneca’s key breast cancer catalyst? - Investing.com Nigeria
ASTRAZENECA : Jefferies remains its Buy rating - marketscreener.com
AstraZeneca Gears Up for Phase 3 Trial of Weight-loss Drug - marketscreener.com
IAMS WEALTH MANAGEMENT, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results - GuruFocus
Elecoglipron cut nearly 12% of body weight in study, AstraZeneca says - AOL.com
AstraZeneca unveils data behind Phase III-bound oral GLP-1 - FirstWord Pharma
AstraZeneca’s oral GLP-1 advances to Phase III after strong trial results - Investing.com Nigeria
AstraZeneca obesity pill shows 10.5% weight loss in trial By Investing.com - Investing.com UK
AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio - marketscreener.com
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial - marketscreener.com
AstraZeneca advances weight-loss pill to take aim at obesity leaders - Financial Times
ADA 2026: AstraZeneca Advances Oral GLP-1 Elecoglipron Into Phase III After Positive Trial Data - Citeline News & Insights
AstraZeneca plc stock (GB0009895292): Oncology pipeline, obesity push and latest trial updates in fo - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential - DirectorsTalk Interviews
AstraZeneca hails phase 3 trial results of inhibitor Ultomiris - London South East
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
AstraZeneca warns it could delay Europe drug launchesFT - marketscreener.com
PRESS: AstraZeneca warns it could delay Europe drug launchesFT - London South East
AstraZeneca chief warns group could withhold new drugs in Europe - Financial Times
AstraZeneca Broadens US Growth Push - marketscreener.com
AstraZeneca advances Friday, outperforms market - MarketWatch
AstraZeneca plc stock (GB0009895292): Share price edges higher after 3.1% move and valuation focus - AD HOC NEWS
AstraZeneca (AZN) Stock Gains 3.1% as Bernstein Highlights Overlooked Non-Oncology Potential - parameter.io
AstraZeneca (AZN) Stock: Bernstein's £186 Target Highlights Overlooked Non-Oncology Potential - MoneyCheck
AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment - Blockonomi
AstraZeneca (AZN) Stock: Bernstein Sees 37% Upside as Non-Oncology Gets Ignored - CoinCentral
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History - Yahoo Finance
Bernstein: Why AstraZeneca’s biggest growth opportunity is being overlooked By Investing.com - Investing.com Nigeria
Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca - marketscreener.com
Why is AstraZeneca trending right now - Kalkine Media
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
3.92%
0.08%
大文字化:
|
ボリューム (24 時間):